Genetic variants in CETP increase risk of intracerebral hemorrhage.
Christopher D AndersonGuido J FalconeChia-Ling PhuahFarid RadmaneshH Bart BrouwersThomas W K BatteyAlessandro BiffiGina M PelosoDajiang J LiuAlison M AyresJoshua N GoldsteinAnand ViswanathanSteven M GreenbergMagdy SelimJames F MeschiaDevin L BrownBradford B WorrallScott L SillimanDavid L TirschwellMatthew L FlahertyPeter KraftJeremiasz M JagiellaHelena SchmidtBjörn M HansenJordi Jimenez-CondeEva Giralt-SteinhauerRoberto ElosuaElisa Cuadrado-GodiaCarolina SorianoKoen M van NieuwenhuizenCatharina J M KlijnKristiina RannikmaeNeshika SamarasekeraRustam Al-Shahi SalmanCatherine L SudlowIan J DearyAndrea MorottiAlessandro PezziniJoanna PeraAndrzej UrbanikAlexander PichlerChristian EnzingerBo NorrvingJoan MontanerIsrael Fernandez-CadenasPilar DelgadoJaume RoquerArne LindgrenAgnieszka SlowikReinhold SchmidtChelsea S KidwellSteven J KittnerSalina P WaddyCarl D LangefeldGoncalo AbecasisCristen J WillerSekar KathiresanDaniel WooJonathan Rosandnull nullPublished in: Annals of neurology (2016)
Genetic variants in CETP associated with increased HDL-C raise the risk of ICH. Given ongoing therapeutic development in CETP inhibition and other HDL-raising strategies, further exploration of potential adverse cerebrovascular outcomes may be warranted. Ann Neurol 2016;80:730-740.